Sigma-1 receptor agonists have been associated with neuroplasticity, neuroprotection, and cognitive function in the brain [21,22,23], and the sigma-2 receptor has been proposed as a potential therapeutic target for schizophrenia and Alzheimer’s disease [24]; however, their EEG effects are currently unclear. This evidence concerns the gene TMEM97 and early-onset autosomal dominant Alzheimer disease.